Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)

被引：0

作者：

Kuzuya, T. ^{[1
]}

Yamashita, T. ^{[2
]}

Takehara, T. ^{[3
]}

Aikata, H. ^{[4
]}

Kato, N. ^{[5
]}

Hiasa, Y. ^{[6
]}

Nakamura, S. ^{[7
]}

Morimoto, N. ^{[8
]}

Moriguchi, M. ^{[9
]}

Ikeda, M. ^{[10
]}

Inoue, J. ^{[11
]}

Tani, J. ^{[12
]}

Ueno, Y. ^{[13
]}

Chayama, K. ^{[14
]}

Tateishi, R. ^{[15
]}

Kawamura, Y. ^{[16
]}

Furuse, J. ^{[17
]}

Kudo, M. ^{[18
]}

Yamamoto, K. ^{[19
]}

Kokudo, N. ^{[20
]}

机构：

[1] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan

[2] Kanazawa Univ, Gastroenterol Dept, Kanazawa, Ishikawa, Japan

[3] Osaka Univ, Gastroenterol & Hepatol, Suita, Osaka, Japan

[4] Hiroshima Prefectural Hosp, Gastroenterol, Minami, Japan

[5] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan

[6] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Toon, Japan

[7] Japanese Red Cross Soc, Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[8] Jichi Med Univ Hosp, Dept Med, Div Gastroenterol, Shimotsuke, Tochigi, Japan

[9] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[11] Tohoku Univ Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan

[12] Kagawa Univ, Fac Med, Grad Sch Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan

[13] Yamagata Univ, Gastroenterol, Fac Med, Yamagata, Japan

[14] Hiroshima Univ Hosp, Collaborat Res Lab Med Innovat, Hiroshima, Japan

[15] Univ Tokyo Hosp, Dept Gastroenterol, Bunkyo ku, Tokyo, Japan

[16] Toranomon Gen Hosp, Hepatol, Minato, Japan

[17] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[18] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[19] Yokohama City Univ Med, Dept Biostat, Yokohama, Kanagawa, Japan

[20] NCGM Natl Ctr Global Hlth & Med, Surg, Shinjuku Ku, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.283

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

148P

引用

页码：S1531 / S1532

页数：2

共 50 条

[1] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
Ikeda, M.
Kato, N.
Kagawa, T.
Yamashita, T.
Moriguchi, M.
Nakamura, S.
Sawada, K.
Iijima, H.
Kamoshida, T.
Nakao, K.
Ohkawa, K.
Sugimoto, R.
Takehara, T.
Harada, M.
Yamamoto, Y.
Ito, T.
Kudo, M.
Kokudo, N.
Yamamoto, K.
Furuse, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1467 - S1467
[2] Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting
Takehara, T.
Kato, N.
Aikata, H.
Kuzuya, T.
Hiasa, Y.
Nakamura, S.
Yamamoto, K.
Morimoto, N.
Sakamori, R.
Kawamura, Y.
Tsuchiya, K.
Ueshima, K.
Hiraoka, A.
Nakano, M.
Kokudo, N.
Furuse, J.
Moriguchi, M.
Yamashita, T.
Ikeda, M.
Kudo, M.
ANNALS OF ONCOLOGY, 2024, 35 : S1480 - S1481
[3] Association of skeletal muscle mass with safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the ELIXIR study
Hiraoka, A.
Aikata, H.
Moriguchi, M.
Ikeda, M.
Morimoto, N.
Tsuchiya, K.
Takehara, T.
Nagai, H.
Sakamori, R.
Nakamura, S.
Tsuji, K.
Kuroda, H.
Shimizu, M.
Shiina, S.
Yamasaki, T.
Kudo, M.
Kokudo, N.
Furuse, J.
Yamamoto, K.
Yamashita, T.
ANNALS OF ONCOLOGY, 2024, 35 : S660 - S661
[4] Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis
Kim, S.
Lee, S. Y.
Park, Y. G.
Kim, H-D.
Lee, J. J. X.
Ryu, M. H.
Ryoo, B-Y.
Tai, D. W. M.
Yoo, C.
ANNALS OF ONCOLOGY, 2023, 34 : S609 - S610
[5] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Hsu, C-H.
Lee, M. S.
Lee, K-H.
Numata, K.
Stein, S.
Verret, W.
Hack, S.
Spahn, J.
Liu, B.
Huang, C.
He, R.
Ryoo, B-Y.
ANNALS OF ONCOLOGY, 2019, 30
[6] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Lee, M.
Ryoo, B-Y.
Hsu, C-H.
Numata, K.
Stein, S.
Verret, W.
Hack, S.
Spahn, J.
Liu, B.
Abdullah, H.
He, R.
Lee, K-H.
ANNALS OF ONCOLOGY, 2019, 30 : 875 - 875
[7] Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo plus Bev): ARISE study
Ueshima, K.
Nishida, N.
Hagihara, S.
Minami, Y.
Ida, H.
Takita, M.
Chishina, H.
Morita, M.
Aoki, T.
Kudo, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1542
[8] Efficacy of atezolizumab (atezo) plus bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
He, A. R. R.
Numata, K.
Lee, K-H.
Hsu, C-H.
Lee, J.
Morimoto, M.
Verret, W.
Hack, S. P.
Spahn, J.
Liu, B.
Ryoo, B-Y.
ANNALS OF ONCOLOGY, 2020, 31 : S690 - S690
[9] Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Kai, Machiko
Hikita, Hayato
Kazuki, Maesaka
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kaneko, Akira
Iio, Sadaharu
Nawa, Takatoshi
Kakita, Naruyasu
Morishita, Naoki
Hiramatsu, Naoki
Usui, Takeo
Imanaka, Kazuho
Doi, Yoshinori
Sakakibara, Mitsuru
Yoshida, Yuichi
Oze, Tsugiko
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
PLOS ONE, 2024, 19 (01):
[10] CLINICAL FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
Maesaka, Kazuki
Hikita, Hayato
Kai, Machiko
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY, 2023, 78 : S1813 - S1813

← 1 2 3 4 5 →